TAO Synergies Inc
Follow $TAOX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TAOX by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TAOX moving today?
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TAOX overview
Related filings and maps
Congress activity in TAOX
No receipt-qualified Congressional disclosure is present for TAOX in the cached public ledger.
TAOX contract awards, year to date.
Public federal awards linked to this ticker.
TAOX lobbying filings, year to date.
Registered lobbying filings matched to TAO Synergies Inc.